CRB-913
Obesity and related conditions
Phase 1Active; Phase 1a complete, dose-range study planned
Key Facts
Indication
Obesity and related conditions
Phase
Phase 1
Status
Active; Phase 1a complete, dose-range study planned
Company
About Corbus Pharmaceuticals
Founded in 2009, Corbus Pharmaceuticals is a publicly-traded company focused on advancing targeted treatments for oncology and metabolic diseases. Its strategy leverages deep biological insight into mechanisms like Nectin-4 in cancer and peripheral CB1 receptors in obesity. The company has progressed its lead oncology asset, CRB-701, into dose optimization studies and recently reported positive Phase 1a safety data for its obesity candidate, CRB-913, positioning it for continued clinical development.
View full company profile